Back to Search
Start Over
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
- Source :
- Blood. 120:5185-5187
- Publication Year :
- 2012
- Publisher :
- American Society of Hematology, 2012.
-
Abstract
- Persistence or recurrence of minimal residual disease (MRD) after chemotherapy results in clinical relapse in patients with acute lymphoblastic leukemia (ALL). In a phase 2 trial of B-lineage ALL patients with persistent or relapsed MRD, a T cell–engaging bispecific Ab construct induced an 80% MRD response rate. In the present study, we show that after a median follow-up of 33 months, the hematologic relapse-free survival of the entire evaluable study cohort of 20 patients was 61% (Kaplan-Meier estimate). The hema-tologic relapse-free survival rate of a subgroup of 9 patients who received allogeneic hematopoietic stem cell transplantation after blinatumomab treatment was 65% (Kaplan-Meier estimate). Of the subgroup of 6 Philadelphia chromosome–negative MRD responders with no further therapy after blinatumomab, 4 are in ongoing hematologic and molecular remission. We conclude that blinatumomab can induce long-lasting complete remission in B-lineage ALL patients with persistent or recurrent MRD. The original study and this follow-up study are registered at www.clinicaltrials.gov as NCT00198991 and NCT00198978, respectively.
- Subjects :
- Adult
Oncology
Pediatrics
medicine.medical_specialty
Neoplasm, Residual
medicine.medical_treatment
Immunology
Phases of clinical research
Antineoplastic Agents
Kaplan-Meier Estimate
Hematopoietic stem cell transplantation
Biochemistry
Disease-Free Survival
Recurrence
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
hemic and lymphatic diseases
Acute lymphocytic leukemia
Internal medicine
Antibodies, Bispecific
medicine
Humans
Transplantation, Homologous
Survival rate
Survival analysis
business.industry
Hematopoietic Stem Cell Transplantation
Cell Biology
Hematology
medicine.disease
Combined Modality Therapy
Survival Analysis
Minimal residual disease
Transplantation
Blinatumomab
business
Follow-Up Studies
medicine.drug
Subjects
Details
- ISSN :
- 15280020 and 00064971
- Volume :
- 120
- Database :
- OpenAIRE
- Journal :
- Blood
- Accession number :
- edsair.doi.dedup.....6796b72b7e2024d2977495a02402f24f